Full text
Earnings transcript
Read the complete earnings call transcript.
ENTA
Enanta Pharmaceuticals, Inc.
$13.14
0.17
(1.31%)
[ms_data_label text=’Delayed data’]
| Exchange: | NASDAQ |
| Market Cap: | 305.067M |
| Shares Outstanding: | 12.746M |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Biotechnology | |||||
| CEO: | Jay R. Luly | |||||
| Full Time Employees: | 131 | |||||
| Address: |
| |||||
| Website: | https://www.enanta.com |
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 79,204 | 67,635 | 65,324 |
| Gross Profit | 79,204 | 67,635 | 60,738 |
| EBITDA | -123,476 | -104,512 | -70,779 |
| Operating Income | -137,207 | -121,691 | -85,349 |
| Net Income | -133,816 | -116,045 | -81,889 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 462,275 | 376,652 | 280,732 |
| Total Liabilities | 245,540 | 247,838 | 216,015 |
| Total Stockholders Equity | 216,735 | 128,814 | 64,717 |
| Total Debt | 26,513 | 226,058 | 201,056 |
| Cash and Cash Equivalents | 85,388 | 37,233 | 32,298 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | -103,154 | -78,764 | -19,272 |
| Capital Expenditure | -9,058 | -17,948 | -12,896 |
| Free Cash Flow | -112,212 | -96,712 | -32,168 |
| Net Income | -133,816 | -116,045 | -81,889 |
| Net Change in Cash | 41,394 | -48,155 | -5,543 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 50,967.353 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 62,773.828 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 57,100 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | -62,773.828 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | -50,967.353 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | -57,100 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | -52,761.796 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | -40,201.933 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | -46,725.842 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 31,178.188 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 38,400.547 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 34,929.704 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | -2.190 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | -1.880 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | -2.470 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 2 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 1 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Solid Financial Position: ENTA demonstrates a stable balance sheet with significant cash and cash equivalents, as reflected in the Balance Sheet data. A high current ratio (from Key Metrics) indicates strong liquidity to cover short-term liabilities, providing financial flexibility for research and development initiatives.
- Positive Revenue Trends: Income Statement data shows consistent revenue generation, supported by specific product categories in the Revenue Product Segments. This indicates a reliable income stream within the biotechnology industry, as per the Industry and Sector data.
- Strong Operating Cash Flow: Cash Flow Statements highlight robust net cash provided by operating activities, alongside positive free cash flow. This suggests operational efficiency and the ability to fund internal growth or reduce debt without external financing.
- Industry Positioning: ENTA operates in the biotechnology sector (from Company Profile), which shows favorable long-term performance trends (Industry and Sector performance metrics). This aligns with broader sector growth, providing a competitive edge over peers in less dynamic industries.
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about ENTA valuation
Is Enanta Pharmaceuticals, Inc. (ENTA) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Enanta Pharmaceuticals, Inc. (ENTA) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is ENTA a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether ENTA trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is ENTA’s P/E ratio?
You can see ENTA’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for ENTA?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is ENTA a good long-term investment?
Whether ENTA fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
ENTA
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
[ms_data_label text="Daily snapshot"]
1.31
Trading Metrics:
| Open: | [ms_cell_or_dash table='trading_quote' column='open'] | Previous Close: | [ms_cell_or_dash table='trading_quote' column='previousClose'] | |
| Day Low: | [ms_cell_or_dash table='trading_quote' column='dayLow'] | Day High: | [ms_cell_or_dash table='trading_quote' column='dayHigh'] | |
| Year Low: | 4.09 | Year High: | 17.15 | |
| Price Avg 50: | 13.41 | Price Avg 200: | 11.17 | |
| Volume: | 86027 | Average Volume: | 161655 |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeENTA full analysis
Welcome to MARKETSNAP’s SWOT analysis for Enanta Pharmaceuticals! If you’re looking to build wealth through smart, long-term investments, you’re in the right place. Today, we’re diving deep into Enanta Pharmaceuticals, a biotech player that might not be a household name but has some intriguing aspects worth exploring. Let’s break down what this company is about, check out the latest buzz and performance, and then get into the nitty-gritty with a full SWOT analysis to see if this stock deserves a…
Could not create stock discussion for ENTA
